Southern Research is redefining bioanalytical support for the next generation of antibody–drug conjugates by combining deep mechanistic insight with the operational rigor of our GLP-compliant BSL-1/2/3 facilities. Our scientists deploy high-resolution mass spectrometry and orthogonal LC methods to elucidate linker stability and drug-to-antibody ratios, then couple those data with 3-D tumor-spheroid platforms that quantify intracellular trafficking and bystander effects under physiologically relevant conditions. Integrated PK, safety, and tox programs seamlessly link in vitro findings with in vivo models, generating the cohesive data packages regulators now expect for IND submissions. During the ADC Therapeutics Exchange round-table, we will share how this assay innovation shortens CMC and clinical timelines, de-risks development, and partners with sponsors to unlock the full therapeutic promise of ADC 2.0.